Three companies, each working on a specific, documented problem in healthcare: controlled-substance generics, chemotherapy resistance, and opioid risk prediction.
Select a company to explore
WES Pharma is a DEA-certified U.S. generic pharmaceutical manufacturer based in Westminster, Maryland. The company operates a 32,000 sq ft FDA cGMP facility with an active DEA Schedule II-V manufacturing registration. Roughly 200 facilities in the entire United States hold this license. WES targets controlled substance generics in CNS, ADHD, sleep, and pain management.
Offshore generic manufacturers cannot hold a U.S. DEA manufacturing registration for Schedule II-IV controlled substances. WES already holds this license, along with an established DEA quota history that no new entrant can replicate.
DEA allocates annual Schedule II production quotas based on production history. WES's existing quota record is a defensible asset.
Oral suspensions, solutions, chewable ER tablets, and ODT formulations require specialized expertise beyond standard oral solids.
Buy America preferences, FDA scrutiny of offshore supply chains, and VA/DoD procurement all favor a Maryland facility with Tier-1 distributor relationships already in place.
Bacteria that live in and around tumors release a protein called DnaK, which lowers p53. Cisplatin and 5-FU need p53 to work. DnaK Therapeutics is building a drug that blocks bacterial DnaK and a test that finds the patients who carry it. The company is based at USF CONNECT in Tampa and is funded in part by a 2025 award from the Casey DeSantis Florida Cancer Innovation Fund.
Fusobacterium nucleatum, Helicobacter pylori, and several Mycoplasma species live in and around tumors in the digestive tract and beyond. All three release a nearly identical form of DnaK.
Bacterial DnaK lowers p53, the protein that stops a damaged cell from dividing. It also blocks DNA repair. Without enough p53, cisplatin and 5-FU do less.
Small-molecule inhibitors of bacterial DnaK, given alongside a patient's existing chemotherapy, are meant to bring p53 back and restore the drugs' effect.
Lead optimization. Dozens of candidate molecules are being tested for safety, efficacy, and off-target effects.
GATC Health's predictive AI is narrowing the candidate list. First results are expected at the end of 2026 and final results in 2027.
A test that measures how much bacterial DnaK a patient carries, so the therapy goes to the people who have the protein. Candidates are preclinical and have not been tested in humans.
SOAP uses machine learning to flag patients at elevated risk of opioid use disorder months before a crisis would usually show up, while there is still time to change the prescription plan. We are looking for health systems and payers to pilot it.
Connects to existing systems. No manual data re-entry. Runs on live clinical data.
40+ clinical, behavioral, social, and prescription variables evaluated per patient.
Risk scores show up inside the tools clinicians already use.
Illustrative example, not patient data
If your work connects technology and healthcare, or you're looking to invest in this space, we want to talk.
We back healthcare companies that already have clinical validation and the data to prove it works.
We can't solve these problems alone. We're looking for founders, clinicians, and investors who want to build with us.